Molecular oncology plays a pivotal role in diagnosing and managing haematological
neoplasms, including leukemias, lymphomas, and myelomas. Advanced techniques such as RT-PCR, quantitative PCR, and next-generation sequencing (NGS) detect genetic
mutations, chromosomal translocations, and molecular markers that guide classification,
risk stratification, and targeted therapy selection. These tests enable precise diagnosis,
minimal residual disease (MRD) monitoring, and early detection of relapse, ensuring timely
treatment adjustments. By integrating molecular profiling into routine hemato-pathology,
clinicians can deliver personalised, evidence-based care, improving survival outcomes.
CMDL’s comprehensive hematologic oncology panel supports physicians in making
informed decisions, ultimately enhancing patient care and prognosis.
